Effect of Favipiravir on outpatient treatment of Covid-19

Study the effect of Favipiravir on the outpatient treatment Covid-19 patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171219037964N3

Enrollment

Registered

2020-12-02

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. U07COVID-19, virus identified

Interventions

Intervention 1: Intervention group: patients in this group will be treated by Favipiravir 200miligram, 8 pills (2 pills, 4 times a day) for 5 days. Intervention 2: Control group: patients in this grou

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: definite case of Covid-19 age over 18 presented within 5 days from the start of sign and symptoms

Exclusion criteria

Exclusion criteria: severe cases with SpO2 under 90 using an antiviral in previous two weeks previous infection with covid-19 using an steroid in previous two weeks being under treatment with steroid previous allergic to Favipiravir renal failure hepatic failure pregnancy lactating

Design outcomes

Primary

Measure	Time frame
Treatment failure. Timepoint: days 3, 7, 14, 21, 28 from the start of treatment. Method of measurement: interview with patients.;Side effects. Timepoint: days 3 and 7 after the start of treatment. Method of measurement: interview with patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Amra

Esfahan University of Medical Sciences

Amra@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026